- Report
- March 2025
- 522 Pages
Global
From €4335EUR$4,950USD£3,763GBP
- Report
- March 2025
- 415 Pages
Global
From €4335EUR$4,950USD£3,763GBP
- Report
- June 2025
- 72 Pages
Global
From €1708EUR$1,950USD£1,482GBP
€2627EUR$3,000USD£2,280GBP
- Report
- February 2026
- 503 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- October 2025
- 153 Pages
Global
From €4073EUR$4,650USD£3,535GBP
- Report
- October 2025
- 180 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- March 2025
- 120 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- March 2025
- 119 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- November 2025
- 199 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- February 2026
- 285 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 461 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 381 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 393 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 385 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 176 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 216 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 144 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 389 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 379 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 482 Pages
Global
From €5124EUR$5,850USD£4,447GBP

Phase II Clinical Trials are a critical step in the drug development process. They are designed to evaluate the safety and efficacy of a drug or medical device in a larger group of people than Phase I trials. The Phase II trial market is a subset of the larger clinical trial market, and is composed of pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic institutions.
Phase II trials are typically conducted in multiple countries, and involve a larger number of participants than Phase I trials. They are designed to assess the efficacy of a drug or medical device in a larger population, and to identify any potential side effects. The results of Phase II trials are used to determine whether a drug or medical device should proceed to Phase III trials.
Some of the companies in the Phase II trial market include Pfizer, Merck, Novartis, Johnson & Johnson, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Eli Lilly, and Sanofi. CROs such as Parexel, Quintiles, and Covance also play a significant role in the Phase II trial market. Show Less Read more